Form 4: Aligos Therapeutics Director Acquires Stock Options

Aligos Therapeutics Director Peter Hirth acquired 5,860 stock options with an exercise price of $5.50, vesting fully on the first anniversary of the grant date or before the 2027 annual meeting.

Summary

• Peter Hirth, a Director at Aligos Therapeutics, Inc., was granted 5,860 stock options on June 25, 2026.
• These options have an exercise price of $5.50 per share.
• The options will vest and become exercisable in full on the earlier of the first anniversary of the grant date or immediately prior to the Issuer's annual meeting of stockholders in 2027.
• Vesting is contingent upon continuous service to the Issuer through the vesting date.
• Following this transaction, Peter Hirth beneficially owns 5,860 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard grant of stock options to a director, which is a common compensation practice and does not inherently signal positive or negative company performance.

Positives

• Director Hirth's acquisition of stock options aligns his interests with those of other shareholders, potentially indicating confidence in the company's future performance.
• The stock options provide a potential upside for the director if the company's stock price increases above the exercise price of $5.50.

Risks

• The value of the stock options is directly tied to the future performance of Aligos Therapeutics' stock price, which is subject to market volatility and company-specific risks.
• Vesting is contingent on continuous service, meaning any departure from the company before the vesting date would result in forfeiture of the options.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service. The options expire on June 25, 2036.

Industry Context

StockSavvy.ai notes that the grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry as a form of long-term incentive compensation, designed to retain key personnel and align their financial interests with shareholder value.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes value creation. However, the dilutive effect of future share issuance upon option exercise should be considered.
• Employees: This transaction is part of the company's broader compensation strategy, which may influence employee morale and retention if similar incentives are offered.
• Management: The stock options provide a direct financial incentive for management to focus on increasing shareholder value.

Next Steps

• The stock options will vest on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, provided continuous service is maintained.
• The options can be exercised anytime between the vesting date and the expiration date of June 25, 2036.

Key Dates

Keywords

stock options, insider trading, Aligos Therapeutics, Peter Hirth, SEC Form 4, beneficial ownership, vesting schedule, director compensation